Matthew Angel
Chief Executive Officer at Factor Bioscience, Inc.
Net worth: 302 901 $ as of 30/04/2024
Network origin in Matthew Angel first degree
Entity | Entity type | Industry | |
---|---|---|---|
Exacis Biotherapeutics, Inc.
Exacis Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The private company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million.
3
| Subsidiary | Medical/Nursing Services | 3 |
Public Company | Pharmaceuticals: Major | 3 | |
Factor Bioscience, Inc.
Factor Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Factor Bioscience, Inc. develops regenerative medicine by targeting and repairing the molecular origins of disease. It offers gene editing, cell reprogramming and nucleic-acid delivery. The company was founded by Matt Angel and Christopher Rohde in 2011 and is headquartered in Cambridge, MA.
1
| Private Company | Miscellaneous Commercial Services | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Matthew Angel via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
JOHNSON & JOHNSON | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member | |
Frazier Management LLC
Frazier Management LLC Investment ManagersFinance Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington. | Investment Managers | Consultant / Advisor | |
Oxford Bioscience Partners
Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners is an Independent Venture Capital firm founded in 1992 by Edmund Martin Olivier, Alan G. Walton and Cornelius T. Ryan. The firm is headquartered in Boston. | Investment Managers | Private Equity Investor | |
AVANIR PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member | |
THE MEDICINES COMPANY | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
CORREVIO PHARMA CORP. | Pharmaceuticals: Major | Chief Executive Officer | |
COLUCID PHARMACEUTICALS INC | Biotechnology | Director/Board Member | |
Brighton Biotech, Inc.
Brighton Biotech, Inc. BiotechnologyHealth Technology Brighton Biotech, Inc. provides medical research services. It specializes in acquiring and developing pharmaceutical and biotechnology products intended for the treatment and prevention of serious unmet medical needs. The company was founded in 2010 and is headquartered in New York, NY. | Biotechnology | Corporate Officer/Principal | |
University of Virginia | College/University | Doctorate Degree | |
Bates College | College/University | Undergraduate Degree | |
University of Toronto | College/University | Doctorate Degree | |
University of New Hampshire | College/University | Doctorate Degree | |
Wesleyan University | College/University | Undergraduate Degree | |
New York Medical College | College/University | Doctorate Degree | |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Pharmaceuticals: Major | Director/Board Member | |
Pfizer (St. Louis)
Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a private company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | Biotechnology | Corporate Officer/Principal | |
Gordon Research Conferences | Corporate Officer/Principal | ||
The Polycystic Kidney Disease Research Foundation | Corporate Officer/Principal | ||
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Biotechnology | Chairman | |
Cadent Therapeutics, Inc.
Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Silver Creek Pharmaceuticals, Inc.
Silver Creek Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Silver Creek Pharmaceuticals, Inc. develops novel regenerative medicines. The firm focuses on treating cardiovascular disease. Its molecules are designed to promote resilience and regeneration of damaged tissues after acute or chronic injury. The company was founded in 2010 and is headquartered in San Francisco, CA. | Pharmaceuticals: Major | President | |
IGNYTA INC | Biotechnology | Director/Board Member | |
New York University School of Law | College/University | Graduate Degree | |
UNC School of Medicine | College/University | Corporate Officer/Principal | |
BlackThorn Therapeutics, Inc.
BlackThorn Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blackthorn Therapeutics, Inc. manufactures and markets medicines for neuro developmental disorders. The company is headquartered in San Francisco, CA. | Pharmaceuticals: Major | Chairman | |
EPIRUS BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chairman | |
Pamlico BioPharma, Inc.
Pamlico BioPharma, Inc. BiotechnologyHealth Technology Pamlico BioPharma, Inc. provides antibody therapeutics services. It develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. The firms lead program is focused on severe pneumonia caused by streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. The company was founded on 18 December, 2014 and is headquartered in Oklahoma, OK. | Biotechnology | Director/Board Member | |
SSI Strategy LLC
SSI Strategy LLC Miscellaneous Commercial ServicesCommercial Services SSI Strategy owns and operates boutique management consulting firm. Its services include global medical affairs transformation, competency model development, post-merger integration, launch preparation, emerging markets medical affairs: organizational transformation, pharmacovigilance system enhancement and medical planning and tactic prioritization. The company was founded by Gregory Fiore in 2010 and is headquartered in Parsippany, NJ. | Miscellaneous Commercial Services | Founder | |
Novellus LLC
Novellus LLC Pharmaceuticals: MajorHealth Technology Novellus LLC operates as a pharmaceutical company. The company is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
NABRIVA THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
DECIPHERA PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
Tremeau Pharmaceuticals, Inc.
Tremeau Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tremeau Pharmaceuticals, Inc. engages in the developing and delivering of non-opioid pain therapies. The firm product includes TRM-201 (rofecoxib). The company was founded by Bradford C. Sippy and Mark H. N. Corrigan in 2016 and is headquartered in Concord, MA. | Pharmaceuticals: Major | Chief Executive Officer | |
Sollis Therapeutics, Inc.
Sollis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sollis Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company developing novel non-steroid and non-opioid analgesics. The company was founded by Gregory Fiore and Bryan Jones and is headquartered in Columbus, OH. | Pharmaceuticals: Major | Chief Executive Officer | |
ERASCA, INC. | Pharmaceuticals: Major | Director/Board Member | |
China Immunotech (Beijing) Biotechnology Co., Ltd.
China Immunotech (Beijing) Biotechnology Co., Ltd. BiotechnologyHealth Technology China Immunotech (Beijing) Biotechnology Co., Ltd. is a biotechnology company based in Beijing, China. The company's description is written in a mix of Chinese and English, making it difficult to understand. The company was founded in 2018 by Xue Qiang Zhao, Hong Li Zheng, Wei Rui, and Wei Rui has been the CEO since 2018. | Biotechnology | Chief Executive Officer | |
Sudo Biosciences, Inc.
Sudo Biosciences, Inc. Information Technology ServicesTechnology Services Sudo Biosciences, Inc. is a biopharmaceutical company that focuses on designing and developing innovative medicines to improve the lives of patients. Sudo Biosciences is based in Menlo Park, CA, and has operations in other locations. The company's primary focus is on developing treatments that target the tyrosine kinase 2 (TYK2) pseudokinase domain, which is a crucial mediator in cytokine signaling pathways that have been associated with various immune-mediated inflammatory conditions. The CEO of the company is Scott A. Byrd. | Information Technology Services | Director/Board Member | |
Fiore Healthcare Advisors, Inc.
Fiore Healthcare Advisors, Inc. Miscellaneous Commercial ServicesCommercial Services Part of SSI Strategy LLC, Fiore Healthcare Advisors, Inc. provides pharmacovigilance and clinical research consulting services. The private company is based in Boston, MA. The company was founded by Gregory Fiore. Fiore Healthcare Advisors was acquired by SSI Strategy LLC on June 29, 2021. | Miscellaneous Commercial Services | Founder | |
Protypia, Inc.
Protypia, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Inotiv, Inc., Protypia, Inc. provides targeted tissue-based protein and peptide mass spectrometry solutions. The private company is based in Nashville, TN. The company was founded in 2017 by Daniel C. Liebler. Daniel C. Liebler has been the CEO since 2017. Protypia was acquired by Inotiv, Inc. on July 07, 2022 for $11 million. | Miscellaneous Commercial Services | Director/Board Member |
Statistics
International
United States | 44 |
Canada | 5 |
Austria | 2 |
Ireland | 2 |
China | 2 |
Sectoral
Health Technology | 34 |
Consumer Services | 9 |
Commercial Services | 4 |
Finance | 3 |
Distribution Services | 2 |
Operational
Director/Board Member | 33 |
Independent Dir/Board Member | 10 |
Chief Tech/Sci/R&D Officer | 9 |
Corporate Officer/Principal | 9 |
Chairman | 8 |
Most connected contacts
Insiders | |
---|---|
Mark Corrigan | 29 |
James Bristol | 17 |
Gregory Fiore | 7 |
Dorothy Clarke | 5 |
James Pan | 3 |
Christopher Rohde | 2 |
- Stock Market
- Insiders
- Matthew Angel
- Company connections